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I am pleased to have this opportunity to comment about the
burden of skin diseases from a congressional and public
policy perspective. Two years ago Dr Luis A. Diaz, then
President of The Society for Investigative Dermatology (SID),
testified before the appropriations subcommittee of the US
House of Representatives, which funds the National Insti-
tutes of Health (NIH), and indicated the concerns of the SID
regarding the matter of insufficient data about the burden of
skin diseases upon the people of this country. The SID has
testified before the House Appropriations Committee every
year for the past 15 years for research funding to improve
the lives of patients. From the 2001 testimony, I quote:
There are more than 3000 different diseases of the skin,
hair and nails, which in an average year affect about 60
million Americans. The combined annual cost to society
of medical care and lost wages from these conditions is
estimated to be in the billions. The potential cost to indi-
viduals suffering from these conditions include: discomfort
and pain, disfigurement, disability, dependency, and death.
You will be surprised to know, I expect, that informa-
tion regarding the total costs to society of dermatologic
diseases has not been updated since 1979. That
includes incidence, prevalence, mortality and disability,
along with economic costs, including direct costs of in-
patient and out-patient care for physicians and other
health professionals, drugs, administrative costs, hospi-
tal and nursing home care, as well as loss of economic
productivity and activities that are foregone as a result of
disease. Upon learning of these problems from the SID, I
requested that the appropriations subcommittee formally
call for a workshop at the National Institution of Arthritis
and Musculoskeletal and Skin Diseases (NIAMS) to
assess the burden of skin diseases, in collaboration with
other federal agencies and voluntary health and profes-
sional organizations.
The workshop was held in September 2002, and a
preliminary report is available at the NIAMS Web site: http://
www.niams.nih.gov/ne/reports/sci_wrk/2002/burden_skin_
disease.htm. These recommendations were made:
 Workshop participants recommended that core mea-
sures of the burden of skin disease be developed (gene-
ral, skin-specific, and skin-disease-specific) to generate
data on incidence, prevalence, economic burden, qua-
lity of life, disability, and handicap.
 These outcomes should be arrayed in a matrix against
personal, family, and societal impacts.
 The available metrics then should be organized within
this matrix so that gaps can be identified and metric
development prioritized.
It was particularly pleasing to see that the workshop
included input from leaders of many patient organizations.
In May 2003, Dr David Bickers testified about the
workshop and made some specific recommendations.
Again, I requested and obtained language from the
appropriations committee in its bill to carry out those
recommendations. I have been pleased to see that the
Senate Appropriations Committee also included language.
To reinforce our intentions, the Senate–House Conference
Committee on the bill also called for action, including
requesting a ‘‘detailed action plan of Institute activities to
effectively implement the recommendations of workshop
participants.’’ It is a real tribute to the SID that it has shown
so much persistence in this effort and that it enthusiastically
has included the patients’ organizations every step of the
way. The issue now has the attention of key congressional
policy makers, whom I hope will realize that nearly a
quarter-century (1979) has passed without a thorough
inventory of all databases and an updating of the quality
of sources of information about all impacts of the burden of
skin disease. It seems to me that a real opportunity exists
now, because of the work that has already begun, for the
field of skin disease research to create an information
system to provide updated data to policy makers, including
congressional appropriators, so they may make sound
judgments about expenditures of taxpayers’ dollars.
As is widely known, Congress has doubled the budget of
the NIH over the past 5 years, and many members are asking
what research advances are being translated to patient
care—which, after all, is what taxpayers’ dollars are being
spent for. Therefore, any systematic action plan for the
development of data that indicates the size and nature of
the problem involved, and a program of research translation
to patient care, should be welcomed by all policy makers.
With these new data, skin diseases may be an important
model and new paradigms can be established on how
societal needs may be addressed by the best of medical
science founded on fundamental research.
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